ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 136 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,045 | -38.9% | 22,495 | -13.3% | 0.00% | – |
| Q2 2023 | $36,069 | -24.9% | 25,949 | -14.1% | 0.00% | – |
| Q1 2023 | $48,040 | -73.0% | 30,214 | +5.6% | 0.00% | – |
| Q4 2022 | $178,240 | -94.6% | 28,610 | -94.2% | 0.00% | -100.0% |
| Q3 2022 | $3,327,000 | +2276.4% | 496,516 | +2166.6% | 0.00% | – |
| Q2 2022 | $140,000 | +115.4% | 21,906 | +55.3% | 0.00% | – |
| Q1 2022 | $65,000 | -57.5% | 14,105 | +11.4% | 0.00% | – |
| Q3 2021 | $153,000 | -32.0% | 12,667 | +19.2% | 0.00% | – |
| Q2 2021 | $225,000 | -93.6% | 10,630 | -90.5% | 0.00% | -100.0% |
| Q1 2020 | $3,523,000 | +1140.5% | 111,725 | +2243.2% | 0.00% | – |
| Q4 2019 | $284,000 | -95.4% | 4,768 | -96.4% | 0.00% | -100.0% |
| Q2 2019 | $6,145,000 | +2398.0% | 132,085 | +2056.1% | 0.00% | – |
| Q1 2019 | $246,000 | -95.3% | 6,126 | -95.5% | 0.00% | -100.0% |
| Q2 2018 | $5,284,000 | -27.4% | 134,821 | +34.0% | 0.00% | -33.3% |
| Q1 2018 | $7,275,000 | +3.2% | 100,582 | -6.1% | 0.00% | 0.0% |
| Q4 2017 | $7,051,000 | -19.2% | 107,099 | -38.5% | 0.00% | 0.0% |
| Q3 2017 | $8,726,000 | -35.6% | 174,097 | -40.6% | 0.00% | -25.0% |
| Q2 2017 | $13,556,000 | +4690.1% | 292,917 | +3552.3% | 0.00% | – |
| Q1 2017 | $283,000 | -88.4% | 8,020 | -95.4% | 0.00% | -100.0% |
| Q3 2016 | $2,440,000 | +40.1% | 176,197 | -0.0% | 0.00% | 0.0% |
| Q2 2016 | $1,742,000 | -54.9% | 176,229 | -22.9% | 0.00% | -50.0% |
| Q1 2016 | $3,864,000 | +38.3% | 228,501 | +82.1% | 0.00% | +100.0% |
| Q4 2015 | $2,793,000 | -3.2% | 125,478 | +2.6% | 0.00% | 0.0% |
| Q3 2015 | $2,886,000 | -67.1% | 122,337 | +13.9% | 0.00% | -66.7% |
| Q2 2015 | $8,779,000 | -15.7% | 107,368 | -4.5% | 0.00% | -25.0% |
| Q1 2015 | $10,411,000 | +783.0% | 112,435 | +285.8% | 0.00% | – |
| Q4 2014 | $1,179,000 | – | 29,145 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |